Ravulizumab Injection bulk supplier for pharma manufacturers

Ravulizumab Injection Suppliers & Bulk Manufacturers

Available Forms: Concentrate vial (IV infusion)

Available Strengths: 300 mg/3 mL, 1100 mg/11 mL (100 mg/mL)

Pack Sizes: Single vial

Reference Brands: Ultomiris (AstraZeneca / Alexion)

Ravulizumab (Ultomiris, AstraZeneca/Alexion) is a long-acting complement C5 inhibitor for PNH, atypical HUS, generalised myasthenia gravis and NMOSD. Maintenance infusions are given every eight weeks instead of every two weeks with eculizumab. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers and licensees preparing for patent and exclusivity expiry.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Ravulizumab Injection? List it or send an offer →

Product Description:

Ravulizumab is a monoclonal antibody that blocks complement protein C5, stopping the formation of the membrane attack complex that destroys red blood cells in paroxysmal nocturnal haemoglobinuria (PNH) and damages blood vessels, nerves and muscle junctions in other complement-driven diseases. It was engineered from eculizumab to stay in the body about four times longer.

It is approved for PNH, atypical haemolytic uraemic syndrome (aHUS), anti-acetylcholine-receptor-positive generalised myasthenia gravis and AQP4-positive neuromyelitis optica spectrum disorder (NMOSD). After a weight-based loading dose, maintenance infusions are given every eight weeks. As with all C5 inhibitors, patients must be vaccinated against meningococcal infection before starting.

Sourcing notes. Ravulizumab is patented and there is no biosimilar, while eculizumab biosimilars are already available in several markets. Orders are weight-based and high value, so we confirm the vial mix and cold-chain plan before quoting. Eculizumab and its biosimilars are also listed on PharmaTradz.

How Ravulizumab Injection is supplied today, and licensing ahead of patent expiry

Ravulizumab Injection is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Ravulizumab Injection, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Ravulizumab Injection supply →

Back to Listing